Slides from my talk at #EuSEM15 on the management of paediatric pain and sedation for procedures in the Emergency Department with tips to change your practice.
In Pursuit of Excellence - #StEmlynsLIVEnataliemmay
Slides from my talk at #StEmlynsLIVE in Manchester, 9th October 2018, entitled In Pursuit of Excellence and themed around Alice's Adventures in Wonderland
Everything Counts in Small Amounts - Natalie May at DFTB17nataliemmay
Slides to accompany my talk at DFTB17 on compassion in adult and paediatric EM - what can we learn from paeds EM to make care better for adults? Full talk: https://dontforgetthebubbles.com/everything-counts-in-small-amounts-at-dftb17/
It's Not OK: Culture, Communication and Conversations in Paediatric Critical ...nataliemmay
Slides to accompany #smaccMINI talk at #dasSMACC on communication in paediatric critical care. The talk covered
- the influence of culture
- how to communicate around procedures
- conversations with children
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
In Pursuit of Excellence - #StEmlynsLIVEnataliemmay
Slides from my talk at #StEmlynsLIVE in Manchester, 9th October 2018, entitled In Pursuit of Excellence and themed around Alice's Adventures in Wonderland
Everything Counts in Small Amounts - Natalie May at DFTB17nataliemmay
Slides to accompany my talk at DFTB17 on compassion in adult and paediatric EM - what can we learn from paeds EM to make care better for adults? Full talk: https://dontforgetthebubbles.com/everything-counts-in-small-amounts-at-dftb17/
It's Not OK: Culture, Communication and Conversations in Paediatric Critical ...nataliemmay
Slides to accompany #smaccMINI talk at #dasSMACC on communication in paediatric critical care. The talk covered
- the influence of culture
- how to communicate around procedures
- conversations with children
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
• Be creative, thoughtful and flexible with drug-based approach: BE PREPARED
• Address the wider factors affecting pain response
Lots of talks at EuSEM about paediatric pain - why? Why are we talking about pain?
Common presentation – about 50% of attendances involve pain. Back in 1997 Petrack’s paper in Pediatrics suggested children in ED in pain receive analgesia less than adults and that difference is more profound where adult and paediatric EDs are not geographically separate.
But that was 18y ago. In the UK we have standards: analgesia in severe
pain within 20mins, re-evaluate at 60mins. And we audit this regularly - we’ve audited it 6 times, so we must be pretty good at it by now, right?
Something we do badly (RCEM audit) – 2011-2012 (6th iteration) higher proportion receiving pre-hospital analgesia but we are still barely managing to provide analgesia in moderate to severe pain Nationally, only 5% of all audited children received adequate pain relief before arrival in the ED, 43% within 20 minutes of arrival, 57% within 30 minutes and 72% within 60 minutes of arrival. Even in severe pain only 53% received analgesia within 20mins of arrival in ED. And if we are actually reassessing we are not recording that in a way which lends itself to this audit.
Pain is hard to measure. Many children are too young to give a numerical score - and many adults struggle with this too. There are other scales we can use but with something so subjective, it’s difficult to find a valid and reliable measure and I wonder if that’s why sometimes we don't even try.
Why is pain hard to measure? Not easy – multifactorial
Pain and distress
Pain is so much more than nociception and pain pathways
More complex than tissue damage causing neuronal firing - who has a tattoo? Who has more than one tattoo? These people have chosen pain. Not all pain is unpleasant, so much of our pain response is determined by factors other than the extent of tissue damage.
• Pain is more than nociception
But…
Pain affects our clinical assessment. In our search for diagnoses we may miss the point. We should address the reason people come to the ED - yes, they want to know why it hurts, but they’ve come because it hurts, so let’s help with that
Maybe we can rethink the way we approach children in pain to give them a better ED experience
Pain in kids
Complicated by negative emotions surrounding pain, injury and hospital
Understand a little developmentally
toddlers transition from stranger anxiety to separation anxiety – we make their worst nightmares come true
Neonates we thought didn’t feel pain – used to intubate without drugs however now we recognise that pain alters clinical outcomes, brain development and subsequent behaviour. Studies show neonates who experience pain develop increased pain sensitivity and hyperalgesia, and is associated with changes in behavioural stress responses, ultimately leading to psychosomatic pain and psychiatric disorders in later life.
However, inflicting pain to relieve pain - if you want to give IV/IM meds - is not something that most children can rationalise. So let’s think flexibly, creatively about managing pain.
For injury we have a number of options. We can start simply. We can give oral paracetamol and ibuprofen. In the UK we no longer give codeine to under 12s.
We can utilise local anaesthetic – regional blocks, like femoral nerve blocks for femoral shaft fractures can work brilliantly.
We are probably still underusing the intranasal route; diamorphine use is well established and well tolerated but fentanyl and ketamine are other intranasal options.
A study (small admittedly) published in the American Journal of EM this week demonstrated how introduction of a protocol for intranasal fentanyl could reduce time to administration of analgesia for children in pain.
Don’t underestimate the value of splinting and immobilising bony injuries – this can be incredibly helpful. Think sensibly about this: if a child obviously has a fracture without XR then they need an XR – but they’re also going to need an intervention, so why not treat the patient first?
For wounds we have great success in Manchester using LAT gel, TAC gel exists as an alternative – apply to wound, leave 45mins and usually provides sufficient anaesthesia for cleaning and closure. Generally rule of Jenner – if child lets you put it on, they’ll let you complete what’s required. Can supplement with additional lidocaine if required.
Free flowing entonox (50% O2:N2O) is a great adjunct. Require scavenging in dept but use valve with reservoir bag – MAC of 105% means it won’t produce full anaesthesia unless in hyperbaric conditions (ED pressure is high but not hyperbaric…yet)
Children with illnesses can have pain too and similar principles apply. Start simple, don’t be afraid to work up. Anticipate your patient’s needs (so put the ametop on in anticipation that things won’t feel better and don’t be frightened of IV opiates and opioids – if the child needs them, they need them. Titrate slowly and you’ll be ok)
• Be creative, thoughtful and flexible with drug-based approach: BE PREPARED
Pain associated with procedures presents a slightly different set of challenges.
There are two key questions we need to ask before we embark on this journey in the ED
1. Is this necessary? Is there genuine benefit in performing this procedure right now in the ED?
2. Is the ED the most appropriate place? – the answer to this might be multifactorial and include things like staffing capability, skill mix, ED capacity, availability of equipment
Realistically you are going to invest far more time in preparation for the procedure than in doing it
For older children, calm conversations about what is necessary and why and how it is going to happen. It may be helpful to outline or write down the steps involved, to demonstrate equipment or simulate practice.
In terms of full procedural sedation, don’t think of sedation in isolation without analgesia. Local, regional or topical anaesthesia may be used in conjunction with sedation to good effect.
Don’t jump straight in. Stop, think, invest time - it will be worth it. Anticipate the need for intravenous access, apply topical anaesthesia.
• Address the wider factors affecting pain response
Preparation is the key to sedation success and is, I would argue, more important than the medications you choose. Use experienced nurses to help – they are often expert at holding and positioning children
But not everything to do with pain is about drugs
Pain has significant psychological, behavioural, emotional and cultural components.
These can be brought into play to modify and dampen pain responses
Communication – your voice, your demeanour, your words – can determine an atmosphere which can escalate or de-escalate distress.
Parents – your greatest ally. Have them on your team. Pep talk them. They need to know exactly what you expect of them. Reward them afterwards
Play therapists exist for this role – they are the masters! We don’t make enough use of them, involve them early, especially for children for whom procedures are anticipated to be difficult (eg autistic spectrum disorder)
Think about atmosphere – use music, lighting. Music is good for reducing anxiety during procedures (CT scan paper) and also when using ketamine, to reduce emergency phenomena
Use adjuncts which focus on distracting physical sensations, like the buzzy bee: poor evidence base but harms likely few and may work by distraction. Consider warmth (especially for abdominal pain)
Neonates: Swaddling – an ancient practice for neonates with evidence for soothing pain, non-nutritive sucking (dummies, sucrose). Both are recommended in combination with sucking providing quicker resolution of crying and normality of vital signs after painful stimulus and swaddling showing a lesser rebound effect after removal
• Pain is more than nociception
• Be creative, thoughtful and flexible with drug-based approach: BE PREPARED
• Address the wider factors affecting pain response
Please be kind to children – it is in your interest to make things run smoothly. You are investing in future ED attendances, not just in your patient’s childhood but in their experiences into adulthood too.
Thank you!